Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission

被引:15
|
作者
Tallman, MS
Pérez, WS
Lazarus, HM
Gale, RP
Maziarz, RT
Rowe, JM
Marks, DI
Cahn, JY
Bashey, A
Bishop, MR
Christiansen, N
Frankel, SR
García, JJ
Ilhan, O
Laughlin, MJ
Liesveld, J
Linker, C
Litzow, MR
Luger, S
McCarthy, PL
Milone, GA
Pavlovsky, S
Phillips, GL
Russell, JA
Saez, RA
Schiller, G
Sierra, J
Weiner, RS
Zander, AR
Zhang, MJ
Keating, A
Weisdorf, DJ
Horowitz, WM
机构
[1] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, ABMTR Hlth Policy Inst, Milwaukee, WI 53226 USA
[2] Northwestern Univ, Sch Med, Chicago, IL USA
[3] Univ Hosp Cleveland, Ireland Canc Ctr, Cleveland, OH 44106 USA
[4] Ctr Adv Studies Leukemia, Los Angeles, CA USA
[5] Oregon Hlth & Sci Univ, Portland, OR USA
[6] Rambam Med Ctr, Haifa, Israel
[7] Technion Israel Inst Technol, Haifa, Israel
[8] British Childrens Hosp, Bristol, Avon, England
[9] Hop Jean Minjoz, F-25030 Besancon, France
[10] Univ Calif San Diego, La Jolla, CA 92093 USA
[11] NCI, Bethesda, MD 20892 USA
[12] Univ S Carolina, Columbia, SC 29208 USA
[13] Merck Res Labs, Blue Bell, PA USA
[14] Hosp Privado Cordoba, Cordoba, Peia, Argentina
[15] Ibini Sinai Hosp, Ankara, Turkey
[16] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[17] Univ Calif San Francisco, Med Ctr, San Francisco, CA 94143 USA
[18] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
[19] Hosp Univ Penn, Philadelphia, PA 19104 USA
[20] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[21] Angelica Ocampo Hosp, Buenos Aires, DF, Argentina
[22] Res Ctr Fundaleu, Buenos Aires, DF, Argentina
[23] Greenbaum Canc Ctr, Baltimore, MD USA
[24] Tom Baker Canc Inst, Calgary, AB, Canada
[25] Watson Clin LLP, Lakeland, FL USA
[26] Univ Calif Los Angeles, Ctr Hlth Sci, Los Angeles, CA 90024 USA
[27] Hosp Sant Pau, Barcelona, Spain
[28] Tulane Univ, Med Ctr, New Orleans, LA USA
[29] Univ Krankenhaus Eppendorg, Hamburg, Germany
[30] Univ Toronto, Toronto, ON, Canada
[31] Univ Minnesota, Minneapolis, MN USA
关键词
autologous; transplantation; autotransplantation; consolidation; acute myelogenous leukemia;
D O I
10.1016/j.bbmt.2005.10.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Controversy exists over whether pretransplantation consolidation chemotherapy affects the outcome of subsequent autotransplantation for acute myelogenous leukemia (AML). The current study was undertaken to determine the association between previous consolidation and outcome of autotransplantation for AML in first remission. Posttransplantation outcomes of 146 patients receiving no consolidation were compared with those of 244 patients receiving standard-dose (<1 gm/m(2)) and 249 patients receiving high-dose (1-3 gm/m(2)) cytarabine, using proportional hazards regression to adjust for differences in prognostic variables. One-year transplantation-related mortality was similar among the cohorts. Five-year relapse rates were 49% (95% confidence interval CI} = 39%-58%) with no consolidation, 35% (95% CI 29%-42%) with standard-dose cytarabine, and 40% (95% CI = 33%-48%) with high-dose cytarabine (P=.07). Five-year leukemia-free survival rates were 39% (95% CI = 30%-47%) with no consolidation, 53% (95% CI = 46%-60%) with standard-dose cytarabine, and 48% (95% CI = 40%-56%) with high-dose cytarabine (P =.03). Similarly, 5-year overall survival was better in those patients receiving consolidation: 42% (95% CI = 34%-51%) with no consolidation, 59% (95% CI = 52%-65%) with standard-dose cytarabine, and 54% (95% CI = 46%-61%) with high-dose cytarabine (P =.01). Although most patients received 1 or 2 cycles of consolidation, the number of courses had no detectable effect on transplantation outcome. In multivariate analysis, risks of relapse and treatment failure were lower in the patients receiving consolidation, especially among those patients receiving blood cell grafts. Outcomes with standard-dose and high-dose cytarabine were similar. Based on our findings, we recommend that patients with AML in first remission receive consolidation before undergoing autotransplantation. (C) 2006 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:204 / 216
页数:13
相关论文
共 50 条
  • [41] Bullous Pyoderma Gangrenosum in a Patient with Acute Myelogenous Leukemia as a Pathergic Reaction after Bone Marrow Biopsy
    Iris, Nur Efe
    Diz-Kucukkaya, Reyhan
    Arat, Mutlu
    Eris, Zahide
    TURKISH JOURNAL OF HEMATOLOGY, 2017, 34 (04) : 350 - 351
  • [42] Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission
    Collisson, EA
    Lashkari, A
    Malone, R
    Paquette, R
    Emmanouilides, C
    Territo, MC
    Schiller, GJ
    LEUKEMIA, 2003, 17 (11) : 2183 - 2188
  • [43] Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia
    Butler, John T.
    Yashar, William M.
    Swords, Ronan
    AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 (04) : 638 - 651
  • [44] Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia
    Thomas, Xavier
    Dombret, Herve
    HEMATOLOGY, 2007, 12 (01) : 15 - 28
  • [45] Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
    Yuda, Sayako
    Fuji, Shigeo
    Onishi, Akio
    Tanaka, Takashi
    Inamoto, Yoshihiro
    Kurosawa, Saiko
    Kim, Sung-Won
    Fukuda, Takahiro
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (06) : 1152 - 1157
  • [46] MRSA-pyomyositis in a Patient with Acute Myelogenous Leukemia after Intensive Chemotherapy
    Fukushima, Toshihiro
    Iwao, Haruka
    Nakazima, Akio
    Miki, Miyuki
    Sakai, Tomoyuki
    Sawaki, Toshioki
    Tanaka, Masao
    Masaki, Yasufumi
    Hirose, Yuko
    Umehara, Hisanori
    ANTICANCER RESEARCH, 2009, 29 (08) : 3361 - 3364
  • [47] Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report
    N Entz-Werle
    S Suciu
    J van der Werff ten Bosch
    E Vilmer
    Y Bertrand
    Y Benoit
    G Margueritte
    E Plouvier
    P Boutard
    E Vandecruys
    A Ferster
    P Lutz
    A Uyttebroeck
    C Hoyoux
    A Thyss
    X Rialland
    L Norton
    M-P Pages
    N Philippe
    J Otten
    C Behar
    Leukemia, 2005, 19 : 2072 - 2081
  • [48] Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia
    Demirer, T
    Petersen, FB
    Bensinger, WI
    Appelbaum, FR
    Fefer, A
    Rowley, S
    Sanders, J
    Chauncey, T
    Storb, R
    Lilleby, K
    Buckner, CD
    BONE MARROW TRANSPLANTATION, 1996, 18 (01) : 29 - 34
  • [49] HIGH-DOSE CYTOSINE-ARABINOSIDE AS CONSOLIDATION CHEMOTHERAPY FOR ACUTE NONLYMPHOCYTIC LEUKEMIA IN REMISSION
    URABE, A
    MIZOGUCHI, H
    HOSHINO, S
    NOMURA, T
    DAN, K
    TOYAMA, K
    KIMURA, M
    OGAWA, T
    YAMAGUCHI, H
    MUTOH, Y
    FUJIOKA, S
    SAITO, T
    TAKAKU, F
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 1991, 54 (01) : 75 - 77
  • [50] Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission:: the EORTC Children Leukemia Group report
    Entz-Werle, N
    Suciu, S
    ten Bosch, JD
    Vilmer, E
    Bertrand, Y
    Benoit, Y
    Margueritte, G
    Plouvier, E
    Boutard, P
    Vandecruys, E
    Ferster, A
    Lutz, P
    Uyttebroeck, A
    Hoyoux, C
    Thyss, A
    Rialland, X
    Norton, L
    Pages, MP
    Phillippe, N
    Otten, J
    Behar, C
    LEUKEMIA, 2005, 19 (12) : 2072 - 2081